News
-
MannKind Corporation will assume the lease for a Pulmatrix research laboratory located in Bedford, MA, USA, and Pulmatrix will transfer the facility, including all laboratory equipment, to MannKind, the companies said. MannKind says that it plans… Read more . . .
-
RDD 2024, which took place May 5-9 in Tucson, AZ, USA, brought together more than 530 delegates and 70 exhibitors for a meeting that highlighted a number of transitions taking place in the development of OINDPs. Compared… Read more . . .
-
Gerresheimer has announced a $180 million, 194,000 sq ft expansion of its device manufacturing facilities near Atlanta, GA, USA. The company says that the expansion will create more than 400 new jobs at its Georgia… Read more . . .
-
Ferrer has announced that its 2022 agreement with United Therapeutics for distribution rights to Tyvaso treprostinil inhalation solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) outside of the US, Canada,… Read more . . .
-
According to Rigshospitalet spin-out Cessatech, the company has initiated a Phase 3 trial of its CT001 sufentanil / ketamine nasal spray in children seen in the emergency department with moderate to severe pain. In July… Read more . . .
-
Amphastar Pharmaceuticals announced that the FDA has approved the company’s ANDA for a generic version of Teva’s ProAir HFA albuterol MDI for the treatment of asthma and said that it plans to launch the inhaler in… Read more . . .
-
Celon Pharma has disclosed a deal in which it will invest $20 million over 2 years, and Tang Capital will invest $10 million over that same period, in a new US-based company called Novohale Therapeutics… Read more . . .
-
TFF Pharmaceuticals announced the Cleveland Clinic Florida will perform additional preclinical studies of 3 dry powder hemagglutinin antigen/adjuvent vaccine candidates produced under a 2023 SBIR grant to TFF for preclinical development of a dry powder… Read more . . .
-
According to Inimmune, a Phase 1b trial of its INI-2004 TLR4 agonist in people with allergic rhinitis demonstrated dose dependent reduction of nasal congestion compared to placebo in a ragweed challenge test, with a reduction… Read more . . .
-
EVŌQ Bio said that it had positive feedback from the FDA following a pre-IND meeting about EVQ-218 inhaled non-ionic silver nanoparticle, which the company is developing for the treatment of pulmonary bacterial infections in cystic… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.